Search Cancer Clinical Trials
Recruiting
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved systemic therapies
- Prostate Cancer Metastatic
- ARV-766 Part A
- ARV-766 Part B
Phase 1/Phase 2
Interventional
Primary Outcome:
- Part A: Incidence of Dose Limiting Toxicities of ARV-766
- Part A: Number of Patients with Adverse Events as a measure of safety and tolerability of ARV-766
- Part A: Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-766
- Part B: To evaluate the clinical anti-tumor activity of ARV-766 in patients with mCRPC
150
September 2, 2021
- Gender: Male
- Minimum age: 18 Years
- Maximum age: N/A
- Healthy volunteers: No
Arvinas Androgen Receptor, Inc.
Arvinas Inc.
A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05067140
Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.